Comparison
CJC-1295 vs Coenzyme Q10
Side-by-side of CJC-1295 and Coenzyme Q10. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
CJC-1295
CJC-1295 peptide profile: GHRH analog forms (with-DAC ~7-day half-life, no-DAC Mod GRF 1-29 ~30 min), ipamorelin pairing, recovery use, dosing, side effects.
Coenzyme Q10
CoQ10 supplement guide: 100 to 300 mg/day dosing, ubiquinol vs ubiquinone absorption, Q-SYMBIO heart failure data, statin myalgia evidence.
Effects at a glance
CJC-1295
- •GHRH analog that binds the GHRH receptor on pituitary somatotrophs to release endogenous GH
- •DAC variant has ~7 day half-life via albumin binding; non-DAC variant ~30 minutes
- •Teichman 2006 trial showed sustained 2 to 10 fold IGF-1 elevation at 60 to 250 mcg/kg DAC dosing
- •Anecdotal protocols pair non-DAC CJC-1295 with Ipamorelin to mimic pulsatile GH release
- •Side effects: water retention, numbness or tingling at injection site, vivid dreams, transient flushing
- •No completed phase III RCTs; research-use-only and not FDA approved
Coenzyme Q10
- •Q-SYMBIO trial showed 43% reduction in major cardiovascular events at 300 mg/day in heart failure
- •Reduces statin-induced myalgia in some patients at 100-200 mg/day per Banach 2014 meta-analysis
- •Migraine prophylaxis at 300 mg/day daily; AHS lists at Level B for prevention
- •Ubiquinol absorbs 2-3x better than ubiquinone in adults over 60
- •Plasma CoQ10 falls 15-40% with chronic statin therapy
- •Small blood pressure reduction (3-5 mmHg systolic) at 100-200 mg/day
Side-by-side
| Attribute | CJC-1295 | Coenzyme Q10 |
|---|---|---|
| Category | peptide | supplement |
| Also known as | CJC-1295 DAC, CJC-1295 no-DAC, Mod GRF 1-29, tesamorelin analog | CoQ10, ubiquinone, ubiquinol, Q10 |
| Half-life (hr) ↗ | 168 | 34 |
| Typical dose (mg) ↗ | 0.1 | 200 |
| Dosing frequency | weekly (DAC); 1-3x daily (non-DAC) | 1 to 3 times daily with a fat-containing meal |
| Routes | subcutaneous | oral |
| Onset (hr) | 1 | 6 |
| Peak (hr) | 3 | 720 |
| Molecular weight | 3367.83 | 863.36 |
| Molecular formula | C152H252N44O42 | C59H90O4 |
| Mechanism | Binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release. The DAC modification extends plasma residence by tethering the peptide to serum albumin via a maleimide-cysteine bond. | Mobile electron carrier between Complex I/II and Complex III of the mitochondrial electron transport chain. Ubiquinol form acts as a lipid-soluble antioxidant in cell membranes and regenerates oxidized vitamin E. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA | Dietary supplement (most jurisdictions); prescription cardiac medication in Japan |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not scheduled |
| Pregnancy | Insufficient data; not recommended | Limited safety data; precautionary use at standard doses |
| CAS | 446262-90-4 | 303-98-0 |
| PubChem CID | 91971820 | 5281915 |
| Wikidata | Q5012154 | Q140453 |
Safety profile
CJC-1295
Common side effects
- injection-site reactions
- water retention
- numbness or tingling at injection site
- vivid dreams
- transient flushing
- head pressure or mild headache
Contraindications
- pregnancy
- active malignancy
- diabetic retinopathy (theoretical)
- history of pituitary tumor
Interactions
- Ipamorelin: synergistic GH release; commonly co-administered in anecdotal protocols(minor)
- insulin: GH-induced insulin resistance can shift glycemic control over weeks(moderate)
- corticosteroids: blunt GH-axis response; reduce expected efficacy(moderate)
Coenzyme Q10
Common side effects
- mild GI upset (rare)
- headache (rare)
- insomnia at very high doses
Contraindications
- active warfarin therapy without monitoring (modest interaction with INR)
Interactions
- warfarin: structural similarity to vitamin K may modestly reduce warfarin efficacy; monitor INR(moderate)
- antihypertensives: additive blood pressure-lowering at high doses(minor)
- statins: statins reduce CoQ10 synthesis; CoQ10 supplementation does not affect statin efficacy(minor)
- chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)
Which Should You Take?
Coenzyme Q10 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. CJC-1295 is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick CJC-1295.
- → If your priority is growth-hormone axis, pick CJC-1295.
- → If your priority is cardiovascular health, pick Coenzyme Q10.
- → If your priority is healthspan extension, pick Coenzyme Q10.
Edge case: If you want to avoid research-only / gray-market sourcing, Coenzyme Q10 is the more accessible choice.
Default choice: Coenzyme Q10. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for CJC-1295 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between CJC-1295 and Coenzyme Q10?
CJC-1295 and Coenzyme Q10 differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, CJC-1295 or Coenzyme Q10?
CJC-1295 half-life is 168 hours; Coenzyme Q10 half-life is 34 hours.
Can you stack CJC-1295 with Coenzyme Q10?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper